Lv1
10 积分 2024-10-13 加入
FFA intervention on LO2 cells mediates SNX-10 synthesis and regulates MMP9 secretion in LX2 cells via TGF-β1
10小时前
求助中
[Intestinal flora polymorphisms with different lesional stages in an animal model of MAFLD]
1天前
已完结
Resmetirom: First Approval
1个月前
已完结
New advances in novel pharmacotherapeutic candidates for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) between 2022 and 2024
1个月前
已完结
An insight into the updated pharmacotherapy of metabolic-associated fatty liver disease (MAFLD) or metabolic dysfunction-associated steatohepatitis (MASH) in lean individuals: a review
1个月前
已完结
Resmetirom: First Approval
3个月前
已完结
NAFLD and NASH: etiology, targets and emerging therapies
3个月前
已完结
Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies
3个月前
已完结
Regression of hepatic fibrosis after pharmacological therapy for nonalcoholic steatohepatitis
3个月前
已关闭
Antioxidative Hyaluronic Acid–Bilirubin Nanomedicine Targeting Activated Hepatic Stellate Cells for Anti-Hepatic-Fibrosis Therapy
3个月前
已完结
皖公网安备34019202002308
